

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, November 07, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L8	L7 and ((Bucala or Chesney).in.)	17
<input type="checkbox"/>	L7	(MIF or (macrophage adj migration adj inhibitory adj factor)).clm.	159
<input type="checkbox"/>	L6	L1 and ((Bucala or Chesney).in.)	39
<input type="checkbox"/>	L5	L4 and @py<1995	2
<input type="checkbox"/>	L4	L2 same (pharmaceutical or carrier)	141
<input type="checkbox"/>	L3	L2 and (pharmaceutical or carrier)	462
<input type="checkbox"/>	L2	L1 same antibody	520
<input type="checkbox"/>	L1	MIF or (macrophage adj migration adj inhibitory adj factor)	2963

END OF SEARCH HISTORY

Set	Items	Description
S1	158	MIF (W) ANTIBODY
S2	92	RD (unique items)
S3	2	S2 AND PHARMACEUTICAL
S4	12	S2 NOT PY>1995
S5	12	S4 NOT PY>1994
S6	6823	MIF OR (MACROPHAGE (W) MIGRATION (W) INHIBITORY (W) FACTOR)
S7	167	S6 (W) ANTIBODY
S8	4	S7 AND (PHARMACEUTICAL OR CARRIER)
S9	4	RD (unique items)
S10	0	S7 AND (AU=(BUCALA OR CHESNEY))
?		

T S5/FULL/ALL

5/9/1 (Item 1 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0009397618 BIOSIS NO.: 199497418903

**Screening for antibody to Chlamydia pneumoniae by the complement fixation test**

AUTHOR: Fonseca Kevin (Reprint); Kluchka Catherine; Anand Chandar M

AUTHOR ADDRESS: Provincial Lab. Public Health for Southern Alberta, 3030

Hospital Drive, NW, PO Box 2490, Calgary, Alberta T2P 2M7, Canada\*\*Canada

JOURNAL: Diagnostic Microbiology and Infectious Disease 18 (4): p229-233  
1994 1994

ISSN: 0732-8893

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** We performed a retrospective survey for antibody to Chlamydia pneumoniae, by the microimmunofluorescence (MIF) test, on 120 sera that were previously determined to be positive for antibody to ornithosis antigen by the complement fixation (CF) test. The panel of sera comprised 40 paired acute and convalescent sera, and 40 single samples, from 80 patients. Of these patients, 60% were considered to be serologically positive for C. pneumoniae, based on the antibody titers of IgG, IgM, or both. There was no association between the CF titer to ornithosis antigen and the respective IgG or IgM MIF antibody titers. We propose that, in those laboratories routinely using the CF test, sera found to be positive for ornithosis antigen should be further tested by the MIF in order to clarify, both from an epidemiologic and clinical perspective, whether these patients are also serologically positive for C. pneumoniae.

**DESCRIPTORS:**

MAJOR CONCEPTS: Immune System--Chemical Coordination and Homeostasis;  
Infection; Metabolism

BIOSYSTEMATIC NAMES: Chlamydiaceae--Chlamydiales, Rickettsias and  
Chlamydias, Eubacteria, Bacteria, Microorganisms; Hominidae--Primates,  
Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: Chlamydia pneumoniae (Chlamydiaceae); human (Hominidae)

COMMON TAXONOMIC TERMS: Bacteria; Eubacteria; Microorganisms; Animals;  
Chordates; Humans; Mammals; Primates; Vertebrates

MISCELLANEOUS TERMS: ANTIBODY TITER; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M  
; IMMUNOLOGIC METHOD; MICROIMMUNOFLUORESCENCE

**CONCEPT CODES:**

10064 Biochemistry studies - Proteins, peptides and amino acids

10068 Biochemistry studies - Carbohydrates

13004 Metabolism - Carbohydrates

13012 Metabolism - Proteins, peptides and amino acids

34502 Immunology - General and methods

34504 Immunology - Bacterial, viral and fungal

36001 Medical and clinical microbiology - General and methods

36002 Medical and clinical microbiology - Bacteriology

**BIOSYSTEMATIC CODES:**

07121 Chlamydiaceae

86215 Hominidae

5/9/2 (Item 2 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0008982471 BIOSIS NO.: 199497003756

**MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia**

AUTHOR: Bernhagen J; Calandra T; Mitchell R A; Martin S B; Tracey K J;

Voelter W; Manogue K R; Cerami A; Bucala R (Reprint)

AUTHOR ADDRESS: Picower Inst. Med. Res., 350 Community Dr., Manhasset, NY  
11030, USA\*\*USA

JOURNAL: Nature (London) 365 (6448): p756-759 1993 1993

ISSN: 0028-0836

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** Cytokines are critical in the often fatal cascade of events that cause septic shock. One regulatory system that is likely to be important in controlling inflammatory responses is the neuroendocrine axis. The pituitary, for example, is ideally situated to integrate central and peripheral stimuli, and initiates the increase in systemic glucocorticoids that accompanies host stress responses. To assess further the contribution of the pituitary to systemic inflammatory processes, we examined the secretory profile of cultured pituitary cells and whole pituitaries in vivo after stimulation with bacterial lipopolysaccharide (LPS). Here we identify macrophage migration inhibitory factor (MIF) as a major secreted protein released by anterior pituitary cells in response to LPS stimulation. Serum analysis of control, hypophysectomized and T-cell-deficient (nude) mice suggests that pituitary-derived MIF contributes to circulating MIF present in the post-acute phase of endotoxaemia. Recombinant murine MIF greatly enhances lethality when co-injected with LPS and anti-MIF antibody confers full protection against lethal endotoxaemia. We conclude that MIF plays a central role in the toxic response to endotoxaemia and possibly septic shock.

**DESCRIPTORS:**

MAJOR CONCEPTS: Blood and Lymphatics--Transport and Circulation; Cell Biology; Endocrine System--Chemical Coordination and Homeostasis; Immune System--Chemical Coordination and Homeostasis; Infection; Physiology; Toxicology

BIOSYSTEMATIC NAMES: Muridae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: mouse (Muridae)

COMMON TAXONOMIC TERMS: Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Rodents; Vertebrates

MISCELLANEOUS TERMS: BACTERIAL LIPOPOLYSACCHARIDE; ENDOTOXEMIA;

MACROPHAGE MIGRATION INHIBITORY FACTOR; SEPTIC SHOCK

**CONCEPT CODES:**

02506 Cytology - Animal

10066 Biochemistry studies - Lipids

10068 Biochemistry studies - Carbohydrates

12100 Movement

15004 Blood - Blood cell studies

15006 Blood - Blood, lymphatic and reticuloendothelial pathologies

15008 Blood - Lymphatic tissue and reticuloendothelial system

17014 Endocrine - Pituitary

22501 Toxicology - General and methods

31000 Physiology and biochemistry of bacteria

34504 Immunology - Bacterial, viral and fungal

36002 Medical and clinical microbiology - Bacteriology

**BIOSYSTEMATIC CODES:**

86375 Muridae

5/9/3 (Item 3 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0008905382 BIOSIS NO.: 199396069798

**A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island: Evidence of serologic cross-reactivity**

AUTHOR: Kern David G (Reprint); Neill Marguertię A; Schachter Julius

AUTHOR ADDRESS: Memorial Hosp., Providence, RI 01860, USA\*\*USA

JOURNAL: Chest 104 (1): p208-213 1993

ISSN: 0012-3692

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

**ABSTRACT:** Objective: Although Chlamydia pneumoniae is considered a common cause of pneumonia worldwide, the evidence is mainly serologic. Therefore, we examined whether the currently used chlamydial microimmunofluorescence (MIF) antibody test is specific for C. pneumoniae infection. Design and setting: Secondary analysis of data from a cohort study of sarcoidosis among the graduates of ten consecutive apprenticeship classes of fire-fighters and police officers. Participants: One hundred forty-seven young adult men. Measurements: Immunoglobulin G and M antibodies to C. pneumoniae, 15 serovars of C. trachomatis, and 2 strains of C. psittaci as measured by MIF. Results: Evidence of previous C. pneumoniae and C. trachomatis infection (IgG gtoreq 1:16 yet lt 1:512) was present in 108 (73 percent) and 59 (40 percent) subjects, respectively. Serologic evidence of recent C. pneumoniae and C. trachomatis infection (IgM gtoreq 1:16 or IgG gtoreq 1:512) was present in 19 (13 percent) and 14 (10 percent) subjects, respectively. Chlamydia pneumoniae and C. trachomatis IgM titers were highly correlated ( $r=0.80$ ; 95 percent CI, 0.73 to 0.85) while C. pneumoniae and C. trachomatis IgG titers were fairly correlated ( $r = 0.44$ ; 95 percent CI, 0.30 to 0.56). Conclusions: The C. pneumoniae seroprevalence of 86 percent is the highest yet reported. The correlations between C. pneumoniae and C. trachomatis antibody titers suggest that chlamydial MIF may be less specific than is generally appreciated. Moreover, the observed 13 percent seroprevalence of recent C. pneumoniae infection in a healthy working population challenges the serologically based belief that this agent accounts for 6 to 10 percent of community-acquired pneumonia. A more objective, more specific test is needed in the serodiagnosis of C. pneumoniae infection.

**DESCRIPTORS:**

MAJOR CONCEPTS: Clinical Endocrinology--Human Medicine, Medical Sciences; Epidemiology--Population Studies; Immune System--Chemical Coordination and Homeostasis; Infection; Metabolism; Pulmonary Medicine--Human Medicine, Medical Sciences; Serology--Allied Medical Sciences

BIOSYSTEMATIC NAMES: Bunyaviridae--Negative Sense ssRNA Viruses, Viruses, Microorganisms; Chlamydiaceae--Chlamydiales, Rickettsias and Chlamydias, Eubacteria, Bacteria, Microorganisms; Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Viruses--Microorganisms

ORGANISMS: Hantaan virus (Bunyaviridae); Chlamydiaceae (Chlamydiaceae); human (Hominidae); arbovirus (Viruses)

COMMON TAXONOMIC TERMS: Negative Sense Single-Stranded RNA Viruses; Bacteria; Eubacteria; Animals; Chordates; Humans; Mammals; Primates; Vertebrates; Microorganisms; Viruses

MISCELLANEOUS TERMS: SEASONAL VARIATION; STATISTICS

## CONCEPT CODES:

05500 Social biology and human ecology  
10064 Biochemistry studies - Proteins, peptides and amino acids  
10068 Biochemistry studies - Carbohydrates  
12504 Pathology - Diagnostic  
13004 Metabolism - Carbohydrates  
13012 Metabolism - Proteins, peptides and amino acids  
15002 Blood - Blood and lymph studies  
16001 Respiratory system - General and methods  
16006 Respiratory system - Pathology  
34504 Immunology - Bacterial, viral and fungal  
34508 Immunology - Immunopathology, tissue immunology  
36002 Medical and clinical microbiology - Bacteriology  
36504 Medical and clinical microbiology - Serodiagnosis  
37010 Public health - Public health administration and statistics  
37052 Public health: epidemiology - Communicable diseases  
37400 Public health: microbiology - Public health microbiology

## BIOSYSTEMATIC CODES:

03506 Bunyaviridae  
07121 Chlamydiaceae  
86215 Hominidae  
03000 Viruses

5/9/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0008859955 BIOSIS NO.: 199396024371

**The major binding protein of the interferon antagonist sarcolectin in human placenta is a macrophage migration inhibitory factor**

AUTHOR: Zeng Fu-Yue; Weiser Weishui Y; Kratzin Hartmut; Stahl Bernd; Karas Michael; Gabius Hans-Joachim (Reprint)

AUTHOR ADDRESS: Institut Pharmazeutische Chemie, Abt. Glykobiologie  
Angewandte Tumorlektinologie, Philipps-Universitaet, Marbacher Weg 6,  
D-35037 Marburg, Germany\*\*Germany

JOURNAL: Archives of Biochemistry and Biophysics 303 (1): p74-80 1993

ISSN: 0003-9861

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: The interferon antagonist and growth promotor sarcolectin has affinity for negatively charged carbohydrates. Isolation of cellular binding proteins will be a step to elucidate its physiological significance. Thus, resin-immobilized sarcolectin was employed as affinity ligand for chromatographic fractionation of extract from human placenta. Elution with 0.1 M NH<sub>4</sub>OH or with 0.1 M N-acetylneuraminic acid and 1 M NaCl resulted primarily in purification of a protein of molecular mass of about 12 kDa according to gel electrophoretic analysis under denaturing conditions in the presence or absence of reductive agent and 12,470 Da by laser desorption mass spectrometry. The native molecular mass, assessed by gel filtration, is approximately 28 kDa. No evidence for detectable post-translational modification by glycosylation was provided by treatment with N-glycosidase F or sialidase and subsequent electrophoretic analysis. The N-terminal sequence of the major sarcolectin-binding protein is identical to that deduced from the cDNA sequence of a human macrophage migration inhibitory factor (MIF), starting from its third amino acid, over the determined stretch of 22 amino acids. Comparison of the calculated molecular mass of 12,221 of

this factor the experimental determined value of 12,470 excludes any extensive modification of the protein. The sarcolectin binding protein reduces macrophage migration at a concentration of 100 ng/ml in MIF assays. Recombinant migration inhibitory factor and purified sarcolectin-binding protein reacted equally well with anti-MIF antibody in immunoblot analysis and in assays to block binding to sarcolectin. Binding of biotinylated sarcolectin, too, is nearly identical for the two protein preparations. It is optimal in the range pH 7-9 and is markedly impaired optimal in the range pH 7-9 and is markedly impaired by increasing ionic strength. Chemical modification with group-specific reagents revealed that the integrity of carboxyl groups of the sarcolectin-binding protein and of lysine/arginine groups of sarcolectin are primarily important to maintain binding capacity. In addition to contribute to the understanding of the functional significance of sarcolectin this result provides a convenient procedure to purify a lymphokine.

REGISTRY NUMBERS: 87940-72-5: SARCOLECTIN

DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Development;  
Endocrine System--Chemical Coordination and Homeostasis; Metabolism;  
Reproductive System--Reproduction

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata,  
Animalia

ORGANISMS: Hominidae (Hominidae)

COMMON TAXONOMIC TERMS: Animals; Chordates; Humans; Mammals; Primates;  
Vertebrates

CHEMICALS & BIOCHEMICALS: SARCOLECTIN

MISCELLANEOUS TERMS: APPARENT COMPENSATORY BEHAVIOR; CUMULATIVE ANGULAR  
DISORDER; G-ACTIN HINGES; G-ACTIN SWITCHES; LATERAL SLIPPING;  
NONCONSTANT ROTATIONAL OFFSETS; POLYMERIZATION

CONCEPT CODES:

02508 Cytology - Human  
10064 Biochemistry studies - Proteins, peptides and amino acids  
10068 Biochemistry studies - Carbohydrates  
10506 Biophysics - Molecular properties and macromolecules  
12100 Movement  
13012 Metabolism - Proteins, peptides and amino acids  
15004 Blood - Blood cell studies  
15008 Blood - Lymphatic tissue and reticuloendothelial system  
16504 Reproductive system - Physiology and biochemistry  
17002 Endocrine - General  
25502 Development and Embryology - General and descriptive

BIOSYSTEMATIC CODES:

86215 Hominidae

5/9/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

2006 The Thomson Corporation. All rts. reserv.

0003988992 BIOSIS NO.: 198376080427

**ROLE OF LYMPHOKINES IN REGULATION OF MACROPHAGE DIFFERENTIATION**

AUTHOR: ONOZAKI K (Reprint); AKAGAWA K S; HAGA S; MIURA K; HASHIMOTO T;  
TOKUNAGA T

AUTHOR ADDRESS: DEP MICROBIOL, INSTITUTE BASIC MED SCIENCES, UNIV TSUKUBA,  
IBARAKI, 305, JPN\*\*JAPAN

JOURNAL: Cellular Immunology 76 (1): p129-136 1983

ISSN: 0008-8749

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The regulatory mechanism of guinea pig lymphokines was investigated in regard to differentiation of myeloid cells to macrophages. The M-cell line, established from a myeloid leukemia of an SL-strain mouse, was induced to differentiate in vitro into mature macrophages possessing Fc receptors and the ability to phagocytize latex particles by treatment with crude lymphokines. Both concanavalin A- and antigen-induced lymphokines showed the differentiation-inducing factor (D factor) activity. Macrophage migration inhibitory factor/macrophage activation factor (MIF/MAF) purified by an immunoadsorbent column with anti-MIF antibody had no such an activity. The D-factor activity was detected in the lymphokine preparation that was not retained on the immunoadsorbent column. Colony-stimulating factor (CSF) was adsorbed to the immunoadsorbent column, and could be recovered in the purified MIF/MAF preparation. Evidently, the molecular entity of D factor is distinct from MIF/MAF and CSF. A culture supernatant of guinea pig peritoneal macrophages activated with MIF/MAF (CSF) exhibited strong D-factor activity. The supernatant possessed rather reduced CSF activity as compared to that of the original MIF/MAF (CSF) preparation. Thus, MIF/MAF may play an important role in macrophage differentiation by regulating the production of D factor or CSF from macrophages.

REGISTRY NUMBERS: 62683-29-8: COLONY-STIMULATING FACTOR; 11028-71-0:  
CONCANAVALIN A

DESCRIPTORS: GUINEA-PIG MYELOID CELLS MYELOID LEUKEMIA M-1 CELLS  
DIFFERENTIATION INDUCING FACTOR MACROPHAGE MIGRATION INHIBITORY FACTOR  
MACROPHAGE ACTIVATION FACTOR COLONY STIMULATING FACTOR CONCANAVALIN A  
DESCRIPTORS:

MAJOR CONCEPTS: Blood and Lymphatics--Transport and Circulation;  
Development; Immune System--Chemical Coordination and Homeostasis  
BIOSYSTEMATIC NAMES: Leguminosae--Dicotyledones, Angiospermae,  
Spermatophyta, Plantae; Caviidae--Rodentia; Mammalia, Vertebrata,  
Chordata, Animalia

COMMON TAXONOMIC TERMS: Angiosperms; Dicots; Plants; Spermatophytes;  
Vascular Plants; Animals; Chordates; Mammals; Nonhuman Vertebrates;  
Nonhuman Mammals; Rodents; Vertebrates

CHEMICALS & BIOCHEMICALS: COLONY-STIMULATING FACTOR; CONCANAVALIN A  
CONCEPT CODES:

02506 Cytology - Animal  
10054 Biochemistry methods - Proteins, peptides and amino acids  
10058 Biochemistry methods - Carbohydrates  
10064 Biochemistry studies - Proteins, peptides and amino acids  
10068 Biochemistry studies - Carbohydrates  
10504 Biophysics - Methods and techniques  
11314 Chordate body regions - Abdomen  
15002 Blood - Blood and lymph studies  
15004 Blood - Blood cell studies  
15006 Blood - Blood, lymphatic and reticuloendothelial pathologies  
15008 Blood - Lymphatic tissue and reticuloendothelial system  
22008 Pharmacology - Blood and hematopoietic agents  
22018 Pharmacology - Immunological processes and allergy  
24010 Neoplasms - Blood and reticuloendothelial neoplasms  
25508 Development and Embryology - Morphogenesis  
32500 Tissue culture, apparatus, methods and media  
34502 Immunology - General and methods  
34508 Immunology - Immunopathology, tissue immunology  
51522 Plant physiology - Chemical constituents  
54000 Pharmacognosy and pharmaceutical botany



## BIOSYSTEMATIC CODES:

26260 Leguminosae  
86300 Caviidae

5/9/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0003521010 BIOSIS NO.: 198273024937

PRODUCTION OF AN ANTIBODY AGAINST GUINEA-PIG MACROPHAGE MIGRATION  
INHIBITION FACTOR 3. BIOLOGICAL ACTIVITY OF MACROPHAGE MIGRATION  
INHIBITION FACTOR RECOVERED FROM IMMUNO ADSORBENT COLUMN CHROMATOGRAPHY

AUTHOR: ONOZAKI K (Reprint); HAGA S; ICHIKAWA M; HOMMA Y; MIURA K;  
HASHIMOTO T

AUTHOR ADDRESS: INST BASIC MED SCI, UNIV TSUKUBA, IBARAKI-KEN 305, JPN\*\*  
JAPAN

JOURNAL: Cellular Immunology 61 (1): p165-175 1981

ISSN: 0008-8749

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: MIF[macrophage migration inhibition factor]-active substance recovered from the immunoadsorbent column of an anti-MIF antibody was examined for possession of activities of other lymphokines. This MIF-active substance showed no activities of macrophage chemotactic factor (MCF), neutrophil chemotactic factor (NCF), skin-reactive factor (SRF) and vascular permeability factor (VPF). Macrophage activation factor (MAF) activity assessed by stimulation of glucose consumption and stimulation of [3H]glycosamine incorporation was associated with the recovered MIF. MIF apparently could be separated from 4 other lymphokines, MCF, NCF, SRF and VPF, which were thought to induce the delayed type skin reaction. The possibility that MIF is the same molecule as MAF was supported.

DESCRIPTORS: LYMPHOKINE MACROPHAGE ACTIVATION FACTOR DELAYED TYPE SKIN  
REACTION MACROPHAGE CHEMO TACTIC FACTOR NEUTROPHIL CHEMO TACTIC FACTOR SKIN  
REACTIVE FACTOR VASCULAR PERMEABILITY FACTOR

## DESCRIPTORS:

MAJOR CONCEPTS: Biochemistry and Molecular Biophysics; Blood and  
Lymphatics--Transport and Circulation; Immune System--Chemical  
Coordination and Homeostasis; Metabolism

BIOSYSTEMATIC NAMES: Caviidae--Rodentia, Mammalia, Vertebrata, Chordata,  
Animalia

COMMON TAXONOMIC TERMS: Animals; Chordates; Mammals; Nonhuman Vertebrates  
; Nonhuman Mammals; Rodents; Vertebrates

## CONCEPT CODES:

02506 Cytology - Animal

06504 Radiation biology - Radiation and isotope techniques

10010 Comparative biochemistry

10050 Biochemistry methods - General

10054 Biochemistry methods - Proteins, peptides and amino acids

10058 Biochemistry methods - Carbohydrates

10060 Biochemistry studies - General

10064 Biochemistry studies - Proteins, peptides and amino acids

10068 Biochemistry studies - Carbohydrates

10069 Biochemistry studies - Minerals

10504 Biophysics - Methods and techniques

10506 Biophysics - Molecular properties and macromolecules

12100 Movement  
12508 Pathology - Inflammation and inflammatory disease  
13002 Metabolism - General metabolism and metabolic pathways  
13004 Metabolism - Carbohydrates  
13012 Metabolism - Proteins, peptides and amino acids  
14504 Cardiovascular system - Physiology and biochemistry  
15004 Blood - Blood cell studies  
15008 Blood - Lymphatic tissue and reticuloendothelial system  
18501 Integumentary system - General and methods  
18504 Integumentary system - Physiology and biochemistry  
18506 Integumentary system - Pathology  
22100 Routes of immunization, infection and therapy  
34502 Immunology - General and methods  
34508 Immunology - Immunopathology, tissue immunology  
35500 Allergy  
BIOSYSTEMATIC CODES:  
86300 Caviidae

5/9/7 (Item 7 from file: 5)

DIALOG(R) File 5: Biosis Previews(R)

(c) 2006 The Thomson Corporation. All rts. reserv.

0003233799 BIOSIS NO.: 198171052758

**CELLULAR AND HUMORAL HYPER SENSITIVITY TO ADRENAL ANTIGEN IN EXPERIMENTAL ADRENALITIS**

AUTHOR: ISHIZAWA S (Reprint); DANIELS J C

AUTHOR ADDRESS: SECT CLIN IMMUNOL, DEP INTERN MED, UNIV TEX MED BRANCH,  
GALVESTON, TEX 77550, USA\*\*USA

JOURNAL: Immunological Communications 9 (5): p437-452 1980

ISSN: 0090-0877

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: A role for specific cellular, as well as humoral immunity was suggested in experimental adrenalitis. A correlation was sought between cellular and humoral immunity in experimental adrenalitis of the guinea pig. Guinea pigs (GP) (34) were arranged into 4 experimental groups. A group (11 GP) was immunized with a single injection of 250 mg homologous adrenal antigen (HAA) in complete Freund's adjuvant (CFA). A 2nd group (6 GP) was similarly immunized at 1 and 14 days. A 3rd group (9 GP) received 3 such injections at 1, 14 and 21 days. The 4th group (8 control GP) received 0.25 M sucrose in CFA. The following were performed on all groups 10 days after the last injection: lymphocyte response to PHA [phytohemagglutinin] and HAA; HAA-specific macrophage migration inhibition (MIF); antibody titers to HAA by hemagglutination; and histopathology of adrenal, thyroid and testis. Antibody titers reached a mean level of 500 in each of the 3 HAA-immunized groups. In the single injection group, MIF activity and response to PHA were significantly increased when compared to the other immunized groups and to controls. Histopathologic changes were seen in adrenal glands of all immunized groups, but were most remarkable in the single injection group. Progressively fewer changes were observed in double and triple immunized groups. Antibody titers and histological changes were not found in controls. Histopathology correlated better with cell-mediated immune parameters than with specific antibody titers; apparently cell-mediated mechanisms may be the more important factor in pathologic lesions of experimental adrenalitis.

DESCRIPTORS: GUINEA-PIG IMMUNOLOGIC-DRUG ADRENAL HISTO PATHOLOGY THYROID  
 TESTICULAR MACROPHAGE MIGRATION INHIBITION LYMPHOCYTE MITOGEN RESPONSE ANTI  
 ADRENAL ANTIGEN ANTIBODY TITER COMPLETE FREUNDS ADJUVANT PHYTO HEM  
 AGGLUTININ CELL MEDIATED IMMUNE RESPONSE

## DESCRIPTORS:

MAJOR CONCEPTS: Blood and Lymphatics--Transport and Circulation;  
 Endocrine System--Chemical Coordination and Homeostasis; Immune System  
 --Chemical Coordination and Homeostasis; Pharmacology

BIOSYSTEMATIC NAMES: Mycobacteriaceae--Mycobacteria, Actinomycetes and  
 Related Organisms, Eubacteria, Bacteria, Microorganisms; Plantae--  
 Plantae; Caviidae--Rodentia, Mammalia, Vertebrata, Chordata, Animalia

COMMON TAXONOMIC TERMS: Bacteria; Eubacteria; Microorganisms; Plants;  
 Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals;  
 Rodents; Vertebrates

## CONCEPT CODES:

01056 Microscopy - Histology and histochemistry  
 02506 Cytology - Animal  
 10064 Biochemistry studies - Proteins, peptides and amino acids  
 10068 Biochemistry studies - Carbohydrates  
 11108 Anatomy and Histology - Microscopic and ultramicroscopic anatomy  
 12100 Movement  
 12504 Pathology - Diagnostic  
 12508 Pathology - Inflammation and inflammatory disease  
 13004 Metabolism - Carbohydrates  
 13012 Metabolism - Proteins, peptides and amino acids  
 15002 Blood - Blood and lymph studies  
 15004 Blood - Blood cell studies  
 15008 Blood - Lymphatic tissue and reticuloendothelial system  
 16504 Reproductive system - Physiology and biochemistry  
 16506 Reproductive system - Pathology  
 17004 Endocrine - Adrenals  
 17018 Endocrine - Thyroid  
 22018 Pharmacology - Immunological processes and allergy  
 22100 Routes of immunization, infection and therapy  
 25508 Development and Embryology - Morphogenesis  
 31000 Physiology and biochemistry of bacteria  
 32600 In vitro cellular and subcellular studies  
 34504 Immunology - Bacterial, viral and fungal  
 34508 Immunology - Immunopathology, tissue immunology  
 51522 Plant physiology - Chemical constituents  
 54000 Pharmacognosy and pharmaceutical botany

## BIOSYSTEMATIC CODES:

08881 Mycobacteriaceae  
 11000 Plantae  
 86300 Caviidae

5/9/8 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

07256908 PMID: 3609455

**Dissociation of protective immunity against tuberculosis and tuberculin  
 hypersensitivity at a level of lymphokines.**

Hashimoto T; Onozaki K; Homma Y; Fukutomi Y; Ichikawa M

Developments in biological standardization (SWITZERLAND) 1986, 58 (

Pt B) p553-9, ISSN 0301-5149--Print Journal Code: 0427140

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

On the basis of present knowledge on the purification and the action mechanisms of macrophage regulating lymphokines, as summarized in Table VIII, tuberculosis immunity and tuberculin delayed type hypersensitivity may be dissociated at a level of responsible lymphokines. Table VIII. Dissociation of TB-IMM and DTH at a level of lymphokine 1. Purification of mediators resulted in separation of MIF/MAF and MCF 2. Anti-MIF antibody has no suppression of MCF reaction 3. Lipid metabolisms of macrophages stimulated with MIF/MAF and MCF are different 4. MIF/MAF suppresses MCF-reaction through monokines.

Descriptors: \*BCG Vaccine; \*Hypersensitivity, Delayed; \*Lymphokines --immunology--IM; \*Tuberculosis--prevention and control--PC; Animals; BCG Vaccine--immunology--IM; Guinea Pigs; Lymphokines --isolation and purification--IP; Macrophages--immunology--IM

CAS Registry No.: 0 (BCG Vaccine); 0 (Lymphokines)

Record Date Created: 19870918

Record Date Completed: 19870918

5/9/9 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

07014408 PMID: 3518711

**Inhibition of macrophage migration by a factor from ascites fluids of ovarian cancer patients. II. Production and characterization of an anti-MIF antibody.**

Fahlbusch B; Metzner G; Schumann I; Tittel R

Biomedica biochimica acta (GERMANY, EAST) 1986, 45 (3) p371-84,

ISSN 0232-766X--Print Journal Code: 8304435

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

A macrophage migration inhibition factor (OC-MIF) has been isolated from ascites fluid of ovarian cancer patients by affinity chromatography on L-fucose-Sepharose 6B, and characterized biochemically. OC-MIF activity was purified approximately 10 000-fold as compared to the starting material. It exhibits molecular heterogeneity with respect to net charge and molecular weights. Compared to it, purified and radioiodinated OC-MIF is fairly homogeneous and contains a major protein component with a molecular mass of about 45 kD, and two isoelectric points of 3.0-4.0 and about 5.0. Rabbits were immunized with the highly purified MIF material and an antiserum was prepared and was used to prepare immunoabsorbent beads. Beads made with anti-OC-MIF antiserum, but not with rabbit control serum, could remove specifically OC-MIF activity and showed weak reactivity towards Con A induced MIF. Using a radioimmunoassay (RIA) anti-OC-MIF antiserum reacts with OC-MIF and also with Con A induced MIF. This antigenic relationship between conventional MIF and OC-MIF and common biochemical properties suggest that the two mediator substances are very similar and may, perhaps, be identical. Furthermore, the possibility to determine various MIF activities by means of RIA was investigated.

Tags: Female

• Descriptors: \*Antibodies--isolation and purification--IP; \*Ascites; \*Macrophage Migration-Inhibitory Factors--immunology--IM; \*Ovarian Neoplasms--analysis--AN; Chromatography, Affinity; Chromatography, Gel;

Concanavalin A--pharmacology--PD; Electrophoresis, Polyacrylamide Gel; Humans; Immunosorbent Techniques; Isoelectric Focusing; Macrophages--drug effects--DE; Radioimmunoassay

CAS Registry No.: 0 (Antibodies); 0 (Macrophage Migration-Inhibitory Factors); 11028-71-0 (Concanavalin A)

Record Date Created: 19860527

Record Date Completed: 19860527

5/9/10 (Item 3 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

05539541 PMID: 6166838

**Anticomplement immunofluorescence for the titration of antibody to varicella-zoster virus.**

Shigeta S; Baba M; Ogata M; Iijima S; Murai C

Microbiology and immunology (JAPAN) 1981, 25 (3) p295-303, ISSN

0385-5600--Print Journal Code: 7703966

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

Anticomplement immunofluorescence (ACIF) was tested for its use for the titration of antibody against varicella-zoster virus (VZV). ACIF antibody responses of patients with VZV infection were specific for VZV antigen and heterotypic responses to herpes simplex virus type-1 and cytomegalovirus antigens were not observed. Comparative studies of ACIF, membrane immunofluorescence (MIF) and indirect immunofluorescence (IF), using acetone-fixed antigen, were carried out with nonimmune sera and convalescent sera of patients who had recovered from varicella, herpes zoster and Rumsey Hunt disease. Nonspecific staining occurred with some nonimmune sera at a 1:4 dilution in the MIF and IF tests, after freezing and thawing of the serum, but not in the ACIF test. The antibody titers in convalescent sera agreed well in these three methods and the highest titer was obtained by MIF. The titers in ACIF and IF were similar but the ACIF antibody decreased earlier than the IF antibody during convalescence. On the other hand there was a discrepancy between the titers of ACIF and those of MIF and IF antibody in the sera of healthy adults, all sera with titers higher than 10 in the MIF and IF tests had titers below 10 in the ACIF test. The average titer of ACIF antibody declined to less than 10 with increasing age (13 to more than 20 years), whereas the MIF antibody increased during the same period of life.

Descriptors: \*Antibodies, Viral--analysis--AN; \*Complement System Proteins--immunology--IM; \*Herpesvirus 3, Human--immunology--IM; Adolescent; Adult; Animals; Chickenpox--immunology--IM; Child; Child, Preschool; Comparative Study; Fluorescent Antibody Technique; Guinea Pigs; Herpes Zoster--immunology--IM; Humans; Staining and Labeling

CAS Registry No.: 0 (Antibodies, Viral); 9007-36-7 (Complement System Proteins)

Record Date Created: 19810922

Record Date Completed: 19810922

5/9/11 (Item 4 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2006 Dialog. All rts. reserv.

05085073 PMID: 389441

**Production of an antibody against guinea pig MIF. I. Specificity of the anti-MIF antibody.**

Onozaki K; Haga S; Miura K; Ichikawa M; Hashimoto T

Cellular immunology (UNITED STATES) Dec 1979, 48 (2) p258-66, ISSN

0008-8749--Print Journal Code: 1246405

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: MEDLINE; Completed

Subfile: INDEX MEDICUS

Descriptors: \*Antibody Formation; \*Antibody Specificity; \*Macrophage Migration-Inhibitory Factors--immunology--IM; Animals; Electrophoresis, Polyacrylamide Gel; Guinea Pigs; Immunosorbent Techniques; Lymphokines --isolation and purification--IP; Macrophage Migration-Inhibitory Factors --isolation and purification--IP; Rabbits

CAS Registry No.: 0 (Lymphokines); 0 (Macrophage Migration-Inhibitory Factors)

Record Date Created: 19800215

Record Date Completed: 19800215

5/9/12 (Item 1 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2006 The Thomson Corp. All rts. reserv.

0048524 DBR Accession No.: 86-06372 PATENT

**Monoclonal antibodies to macrophage migration-inhibitory factor - useful for cytokine analysis and diagnosis of immune diseases; construction of a hybridoma secreting monoclonal antibody**

PATENT ASSIGNEE: Akad.Wiss.DDR 1985

PATENT NUMBER: DD 230876 PATENT DATE: 851211 WPI ACCESSION NO.: 86-094498 (8615)

PRIORITY APPLIC. NO.: DD 250741 APPLIC. DATE: 830509

NATIONAL APPLIC. NO.: DD 250741 APPLIC. DATE: 830509

LANGUAGE: German

ABSTRACT: New monoclonal antibodies to human macrophage migration-inhibitory factor (MIF) are produced by isolating MIF from tumor-induced ascites, purifying the MIF by alpha-L-fucose-Sepharose 4B affinity chromatography, using the carrier-bound MIF to immunize 6-12 wk old female BALB/c or AB/Jena mice, fusing the hyperimmune mouse spleen cells in a 10:1 ratio with P3-X63-Ag8.653 myeloma cells, selecting stable hybridomas with a MIF antibody production of more than 200 ng/ml by multiple single cell cloning, and isolating the antibodies by precipitation from culture supernatants or from ascites fluid of hybridoma-bearing mice. The monoclonal antibodies are useful for cytokine analysis and for diagnosis of immune diseases. They react specifically with MIF and can be produced in large amounts with uniform quality. The mice used are preferably 8 wk old AB/Jena mice, and fusion is effected using 50% PEG 1,550. The hybridomas (especially cell line 29/24B11) are selected by RIA, after culture on selective HAT medium. (6pp)

DESCRIPTORS: human macrophage migration-inhibitory factor monoclonal antibody prep., appl. to cytokine analysis, immune disease diagnosis etc., hybridoma construction mammal cell culture

SECTION: Pharmaceuticals-Other; Cell Culture-Animal Cell Culture (D5,J1)

?